Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease

New England Journal of Medicine

Volumn 338, Issue 15, 1998, Pages 1009-1015

  Malinow, Manuel R ^a,b,c   Duell, Paul B ^a,b   Hess, David L ^a   Anderson, Peter H ^c   Kruger, Warren D ^d   Phillipson, Beverley E ^b,c   Gluckman, Robert A ^c   Block, Peter C ^b,c   Upson, Barbara M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ADULT; AGED; ARTICLE; CEREAL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; CEREALS; CORONARY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; FOOD, FORTIFIED; HOMOCYSTEINE; HOMOCYSTINE; HUMANS; MALE; MIDDLE AGED; NUTRITION POLICY; VITAMINS;

EID: 0032499126     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199804093381501     Document Type: Article

References (39)

1. Hibbard ED, Smithells RW. Folic acid metabolism and human embryopathy. Lancet 1965;1:1254.
2. Wagner WE, Levine B. Folic acid and neural tube defects. Curr Concepts Nutr 1993;8:1-12.
3. Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-5.
4. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
5. Food standards: amendment of the standards of identity for enriched grain products to require addition of folic acid (21 CFR 136, 137, and 139). Fed Regist 1993;58(197):53305-5312.
6. Subcommittee on the Tenth Edition of the RDAs. Recommended dietary allowances. 10th ed. Washington, D.C.: National Academy Press, 1989.
7. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 1992;41(RR-14):1-7.
8. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid (21 CFR 136, 137, and 139). Fed Regist 1996;61(44):8781-97.
9. Food labeling: health claims and label statements: folate and neural tube defects. Fed Regist 1993;58(197):53254-95.
10. Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr 1996;126:Suppl:1276S-1280S.
11. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237:381-8.
12. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-62.
13. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-33.
14. Malinow MR. Hyperhomocyst(e)inemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990;81: 2004-6.
15. Kang SS, Wong PWK, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-98.
16. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
17. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
18. Duell PB, Malinow MR. Plasma homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997;8:28-34.
19. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-8.
20. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary heart disease. Coronary Artery Dis 1990;1:215-20.
21. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994;7:195-200.
22. Cunniff P, ed. Official methods of analysis of AOAC International. 16th ed. Vol. 1. Agricultural chemicals; contaminants; drugs. Gaithersburg, Md.: AOAC International, 1996.
23. Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter): the Hordaland Homocysteine Study. J Clin Invest 1996;98: 2174-83.
24. Bostom AG, Shemin D, Lapane KL, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49: 147-52.
25. Wouters MG, Boers GH, Blom HJ, et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-5.
26. Rajkovic A, Catalano PM, Malinow MR. Elevated homocyst(e)ine levels with preeclampsia. Obstet Gynecol 1997;90:168-71.
27. Steegers-Theunissen RP, Boers GH, Trijbels FJ, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994; 43:1475-80.
28. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-51.
29. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid fortification of the food supply: potential benefits and risks for the elderly population. JAMA 1996;276:1879-85.
30. Oakley GP Jr. Let's increase folic acid fortification and include vitamin B-12. Am J Clin Nutr 1997;65:1889-90.
31. Kang SS, Wong PWK, Zhou J, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988;37:611-3.
32. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
33. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
34. Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Clin Invest Med 1996;19:171-8.
35. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
36. Malinow MR, Stampfer MJ. Role of plasma homocyst(e)ine in arterial occlusive diseases. Clin Chem 1994;40:857-8.
37. Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995;332:328-9.
38. Albertson AM, Tobelmann RC, Marquart L. Folate consumption and the role of ready-to-eat cereal for American women aged 15 to 50 years. Top Clin Nutr 1997;12:58-68.
39. Shimakawa T, Nieto FJ, Malinow MR, Chambless LE, Schreiner PJ, Szklo M. Vitamin intake: a possible determinant of plasma homocyst(e)ine among middle-aged adults. Ann Epidemiol 1997;7:285-93.